1-15 of 15
Richard Furman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies

Free
Marwan Kwok, Connor Johnson, Eugen Tausch, Liang Li, Chip Stewart, Carrie Cibulskis, Sam Pollock, Johanna van Vliet, Fanny Dao, Satyen Gohil, Madison Lee, Brian Danysh, Anke Schilhabel, Sandra Robrecht, Marc Zapatka, Emanuela Ghia, Laura Rassenti, Lita Freeman, Erica Bhavsar, Andy Itsara, Othman Al-Sawaf, John Allan, Richard Furman, Dan Avi Landau, Thomas Kipps, Adrian Wiestner, Matthias Ritgen, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Stephan Stilgenbauer, Ivana Bozic, Ignaty Leshchiner, Gad Getz, Catherine Wu
Journal: Blood
Blood (2025) 146 (Supplement 1): 245.
https://doi.org/10.1182/blood-2025-245
Published: 2025
Journal Articles

Co-mapping clonal and transcriptional heterogeneity in somatic evolution via got-multi.

Free
Minwoo Pak, Mirca Saurty-Seerunghen, Kellie Wise, Tsega-Ab Abera, Chhiring Lama, Neelang Parghi, Xiaotian Sun, Qi Gao, Liming Bao, Mikhail Roshal, John Allan, Richard Furman, Luciano Martelotto, Anna Nam
Journal: Blood
Blood (2025) 146 (Supplement 1): 244.
https://doi.org/10.1182/blood-2025-244
Published: 2025
Journal Articles

Comparative analysis of characteristics and outcomes in CD5+/FMC7+ lymphoproliferative disorders and classic CLL immunophenotype patients.

Free
Allison Kagerer, Nikita Malakhov, Caitlin Keenan, Zhengming Chen, Amy Chadburn, Richard Furman, John Allan
Journal: Blood
Blood (2025) 146 (Supplement 1): 2121.
https://doi.org/10.1182/blood-2025-2121
Published: 2025
Journal Articles

Impact of FMC7 expression on baseline characteristics and outcomes in CLL patients treated with upfront BTKi monotherapy.

Free
Nikita Malakhov, Allison Kagerer, Caitlin Keenan, Zhengming Chen, Amy Chadburn, Richard Furman, John Allan
Journal: Blood
Blood (2025) 146 (Supplement 1): 2109.
https://doi.org/10.1182/blood-2025-2109
Published: 2025
Journal Articles

Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).

Free
John Allan, Erin Mulvey, Daniel Helbig, Nikita Malakhov, Zhengming Chen, Brittany Hobbie, Sarah Nazir, Jerrod White, Zahra Grant, Jane Matejka, Simone Morris, Liming Bao, Peter Martin, Richard Furman
Journal: Blood
Blood (2025) 146 (Supplement 1): 3886.
https://doi.org/10.1182/blood-2025-3886
Published: 2025
Journal Articles

Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).

Free
John Allan, Andrew Lipsky, Seema Bhat, Suchitra Sundaram, Lubing Wu, Jane Matejka, Brittany Hobbie, Nourhan Hamadi, Simone Morris, Zhengming Chen, Ivo Sah Bander, Madhu Ouseph, Jia Ruan, Amy Chadburn, Adam Kittai, Richard Furman
Journal: Blood
Blood (2025) 146 (Supplement 1): 3681.
https://doi.org/10.1182/blood-2025-3681
Published: 2025
Journal Articles

Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing

Free
Kathleen Burke, Barrett Nuttall, Daniel L. Karl, Megan Callahan, Kerrin Mendler, Steven Criscione, Sergey Naumenko, Elena Bibikova, Andrew Bloecher, Brian Dougherty, J. Carl Barrett, Maurizio Scaltriti, Pablo Cingolani, John C. Byrd, Richard Furman, Jennifer R. Brown, Andrew Mortlock, James Hadfield, Veerendra Munugalavadla
Journal: Blood
Blood (2021) 138 (Supplement 1): 4361.
https://doi.org/10.1182/blood-2021-147113
Published: 2021
Journal Articles

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Free
Michael Wang, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip A. Thompson, Michael Choi, Avyakta Kallam, Ying Zhu, Samhita Chakraborty, Patricia Marinello, Stephen E. Spurgeon
Journal: Blood
Blood (2021) 138 (Supplement 1): 528.
https://doi.org/10.1182/blood-2021-148607
Published: 2021
Journal Articles

The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy

Free
Francesca Arruga, Andrea Iannello, Nikolaos Ioannou, Alberto Maria Todesco, Marta Coscia, Riccardo Moia, Gianluca Gaidano, John N. Allan, Richard Furman, Tiziana Vaisitti, Alan G. Ramsay, Silvia Deaglio
Journal: Blood
Blood (2021) 138 (Supplement 1): 3718.
https://doi.org/10.1182/blood-2021-150183
Published: 2021
Journal Articles

Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Free
John F. Seymour, John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard Furman, Susan M. O'Brien, Jennifer R Brown, Anthony R. Mato, Stephan Stilgenbauer, Nataliya Kuptsova-Clarkson, Paulo Miranda, Dennis Wagner, Kara Higgins, Sophia Sohoni, Wojciech Jurczak
Journal: Blood
Blood (2021) 138 (Supplement 1): 3721.
https://doi.org/10.1182/blood-2021-146228
Published: 2021
Journal Articles

Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD)

Free
Dr. Brian Koffman, Chris Stewart, Liza Avruch, Neil Bailey, Robyn Brumble, John C. Byrd, Alexey V. Danilov, Matthew S. Davids, Richard Furman, Nitin Jain, Neil E. Kay, Nicole Lamanna, Anthony R. Mato, Alan Skarbnik, Chaitra S. Ujjani, John M. Pagel
Journal: Blood
Blood (2021) 138 (Supplement 1): 1927.
https://doi.org/10.1182/blood-2021-145046
Published: 2021
Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Free
Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua D. Hessler, Ta-Ming Liu, Betty Y. Chang, Karilyn M. Larkin, Matthew R. Stefanovski, Danielle L. Chappell, Frank W. Frissora, Lisa L. Smith, Kelly A. Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Amy M. Lehman, Richard Furman, Jeff Sharman, Anjali Mishra, Michael A. Caligiuri, Abhay R. Satoskar, Joseph J. Buggy, Natarajan Muthusamy, Amy J. Johnson, John C. Byrd
Journal: Blood
Blood (2013) 122 (15): 2539–2549.
https://doi.org/10.1182/blood-2013-06-507947
Published: 2013
Includes: Supplemental data
Journal Articles

Targeting Early Events of B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: Suppressed Syk and PLCγ2 Activities Predict Apoptotic Response of Leukemic Cells to Dasatinib

Free
Y. Lynn Wang, MD, PhD, Zibo Song, Pin Lu, John P. Leonard, Morton Coleman, Peter Martin, Chaowei Wu, Francis Y. Lee, Daniel M. Knowles, Richard Furman
Journal: Blood
Blood (2008) 112 (11): 5023.
https://doi.org/10.1182/blood.V112.11.5023.5023
Published: 2008
Journal Articles

Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.

Free
Ellen Ritchie, MD, Lia Gore, MD, Gail J. Roboz, MD, Eric Feldman, MD, Farhad Ravandi, MD, Richard Furman, MD
Journal: Blood
Blood (2006) 108 (11): 1881.
https://doi.org/10.1182/blood.V108.11.1881.1881
Published: 2006
Journal Articles

Prophylactic Low-Dose Aspirin Is Effective as Antithrombotic Therapy in Patients Receiving Combination Thalidomide or Lenalidomide.

Free
Ruben Niesvizky, MD, Deborah M. Martinez-Banos, MD, Udi Y. Gelbshtein, Hearn J. Cho, MD, PhD, Roger N. Pearse, MD, PhD, Faiza Zafar, RPAC, Karen Pekle, NP, Richard Furman, MD, John P. Leonard, MD, Morton Coleman, MD
Journal: Blood
Blood (2005) 106 (11): 3454.
https://doi.org/10.1182/blood.V106.11.3454.3454
Published: 2005